SBC Medical Group Holdings Incorporated (SBC) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$5.69 +4.40% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.75

SBC Medical Group Holdings Incorporated (SBC) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (73% profit margin, 63% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B- β€’ BUY Cap $585.2M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SBC Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is SBC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-01, SBC Medical Group Holdings Incorporated (NASDAQ: SBC) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $5.69 (+4.40% 1D, market cap $585.2M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, SBC ranks #87 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does SBC compare to STLN and AHCO in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Nursing Services), SBC carries a Roarable B- (71/100 RQD), trailing P/E of 11.5x, gross margin of 73.3%, and ROIC of 63.1%. By comparison, STLN (Starling Oncology Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $677.7M) and AHCO (AdaptHealth Corp.) posts a D grade (45/100 RQD, P/E N/A, ROIC 2.2%, cap $808.5M). Among the 5-stock peer group, SRTA leads on earnings multiple (10.2x) while SBC leads on capital efficiency (63.1% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SBC?
β–Ό

Per SBC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001930313), SBC Medical Group Holdings Incorporated generated $173.6M in revenue (-15.5% YoY), $51.0M in net income, and $23.3M in free cash flow against $380.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (73% profit margin)β€”profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.75 (+1.03%)🧬 Cannibal Buyback (-2.36% YoY Shares)βš™οΈ Cash Engine: 16/20 (B+) β€’ 13.4% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY β€’ 68.4% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERBUY β€’ B-
025507510071
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B Β· Rk B-
Cash (16)Whales (11)SEC (13)Macro (15)CEO (16)
Each axis scored 0–20
12M PRICE TARGET CONE+5.8% Base Target
$7 Bull$6 Base$5 Bear
πŸ“¬ FREE SBC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for SBC)Realized 20D OHLCV Swing Band: Β±10.6%
Deterministic 5-Pillar Attribution (71/100 Composite)
πŸ” WHY SBC SCORES 71/100 (B-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+16/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 13.4% FCF Margin ($23.3M FCF) & 73.3% Gross Margin

β–² #2 Bullish Driver: Insider Conviction & Share Dilution+16/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 80% Net Buy β€’ Cannibal Buyback (-2.36% YoY Shares)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
63
Grade C+$5.42-4.8% Next Q
Q2 (-2Q)
66
Grade B-$5.16+2.3% Next Q
Q3 (-1Q)
68
Grade B-$5.28+7.8% Next Q
Current
71
Grade B-$5.69+6.8% Hist 90D Ξ±
Trajectory: C+ (63) β†’ B- (71)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the SBC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 71/100 (B-) score, SBC faces multiple-compression risk if 11.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) β€” any gross margin slip below 70.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($4.87) or 200D SMA ($3.91) invalidates the momentum regime and cuts Target Base ($6.02) toward Bear Floor ($4.67).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SBCβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œSBC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How SBC Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$23.3M (13.4% FCF Margin)
Revenue$173.6MGross Profit $127.3M (73.3%)Cost of Sales $46.3MOp Profit $67.5M (38.9%)OpEx (R&D/SG&A) $59.8MNet Profit$51.0M (29.4%)Tax/Other $16.5M

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $193.5M
FY24
Rev $205.4M
FY25
Rev $173.6M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$173.6M73.3%38.9%$51.0M$23.3M63.1%
FY 2024$205.4M76%34.2%$46.6M$18.0M79.3%
FY 2023$193.5M73.3%36.5%$39.4M$50.7M63.1%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SBC)

  • βœ“Walkthrough of SBC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SBC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +72.42%⚑ TESTING RESISTANCE
2026-10-30O $5.68H $5.70L $5.24C $5.69VOL 155.3K
RES: $5.89SUP: $2.99SMA50: $4.87SMA200: $3.91
$6.00$5.13$4.25$3.38$2.51RES $5.89SUP $2.99$5.692026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SBC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
1.6%/yr Implied 5Y Growth

vs. -15.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SBC today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for SBC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SBC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SBC)

1. Head-to-Head Health Care Peer Comparison (SBC vs. STLN, AHCO, SRTA, AUNA)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SBC Medical Group Holdings Incorporated (SBC) ranks #87 by composite RQD confidence (71/100, grade B-) and #425 by equity capitalization ($585.2M). Within this direct 5-issuer industry benchmark cohort, SRTA leads on earnings valuation at 10.2x trailing P/E, while SBC leads on capital efficiency and profitability with 63.1% ROIC and 73.3% gross margin. SBC currently leads its immediate peer cohort in composite quantitative strength at 71/100 (B-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SBC ACTIVE
SBC Medical Group Holdings Incorporated
B- 71/100 11.5x 73.3% 63.1% +4.40% $585.2M Benchmark Subject
STLN
Starling Oncology Inc.
D- 37/100 β€” β€” -35.0% +0.15% $677.7M /stln-vs-sbc β†’
AHCO
AdaptHealth Corp.
D 45/100 β€” 18.8% 2.2% -1.66% $808.5M /ahco-vs-sbc β†’
SRTA
Strata Critical Medical Inc. (Class A)
D 47/100 10.2x 20.9% -7.1% -0.21% $420.2M /srta-vs-sbc β†’
AUNA
Auna SA (Class A)
C- 61/100 β€” β€” β€” +1.27% $355.3M /auna-vs-sbc β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001930313

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SBC Medical Group Holdings Incorporated (SBC) reported GAAP revenue of $173.6M (-15.5% vs. FY2024 revenue of $205.4M , and -10.3% cumulative change since FY2023) , GAAP net income of $51.0M, operating cash flow of $24.7M, and free cash flow of $23.3M (+29.1% YoY). On the balance sheet, SBC closed FY2025 with $380.4M in total assets against $0 in total debt (Altman Z-Score: 5.46, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $173.6M $51.0M $24.7M $23.3M $380.4M β€”
FY2024 (FY) 2024-12-31 $205.4M $46.6M $20.6M $18.0M $266.1M β€”
FY2023 (FY) 2023-12-31 $193.5M $39.4M $50.7M $50.7M β€” β€”

3. SBC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SBC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, SBC Medical Group Holdings Incorporated (NASDAQ: SBC) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $5.69 (+4.40% 1D, market cap $585.2M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, SBC ranks #87 in composite RQD confidence.

How does SBC compare to STLN and AHCO in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), SBC carries a Roarable B- (71/100 RQD), trailing P/E of 11.5x, gross margin of 73.3%, and ROIC of 63.1%. By comparison, STLN (Starling Oncology Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $677.7M) and AHCO (AdaptHealth Corp.) posts a D grade (45/100 RQD, P/E N/A, ROIC 2.2%, cap $808.5M). Among the 5-stock peer group, SRTA leads on earnings multiple (10.2x) while SBC leads on capital efficiency (63.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SBC?

Per SBC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001930313), SBC Medical Group Holdings Incorporated generated $173.6M in revenue (-15.5% YoY), $51.0M in net income, and $23.3M in free cash flow against $380.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (73% profit margin)β€”profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SBC trading relative to its 50-day, 200-day, and 52-week technical levels?

SBC last traded at $5.69 (+4.40% on volume of 258,973 shares), positioning the stock +16.84% above its 50-day simple moving average ($4.87) and +45.52% above its 200-day simple moving average ($3.91). Across its 52-week range of $2.78 to $5.79, SBC sits at the 96.7% percentile with a 14-day RSI of 51.8 (NEUTRAL RANGE) and an implied next-earnings move of Β±10.6% ($5.09 to $6.29).

SBC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

How profitable is SBC Medical Group Holdings Incorporated (SBC)?

In FY 2025 (10-K), SBC converted $173.6M of revenue into a 73.3% gross margin, 38.9% operating margin, and $23.3M in free cash flow (13.4% FCF margin).

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $213.66 -0.80% AAPL $348.91 +1.48% MSFT $530.14 -0.16% TSLA $403.30 -0.23% PLTR $196.42 -0.20% SOFI $17.61 +2.74% IBIT $43.36 -0.94% GLD $355.78 -1.34%